The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia
The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interdisciplinary Academy of Pain Medicine
2021-11-01
|
| Series: | Perioperative Medicine |
| Subjects: | |
| Online Access: | https://perioperative.org.ua/index.php/prtmdc/article/view/78 |
| _version_ | 1828923914829430784 |
|---|---|
| author | Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina |
| author_facet | Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina |
| author_sort | Dmytro Dmytriiev |
| collection | DOAJ |
| description | The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent. |
| first_indexed | 2024-12-13T22:46:33Z |
| format | Article |
| id | doaj.art-7fad54fdfbf54f1ca15f44a7e80513d8 |
| institution | Directory Open Access Journal |
| issn | 2616-339X 2617-2925 |
| language | Russian |
| last_indexed | 2024-12-13T22:46:33Z |
| publishDate | 2021-11-01 |
| publisher | Interdisciplinary Academy of Pain Medicine |
| record_format | Article |
| series | Perioperative Medicine |
| spelling | doaj.art-7fad54fdfbf54f1ca15f44a7e80513d82022-12-21T23:28:43ZrusInterdisciplinary Academy of Pain MedicinePerioperative Medicine2616-339X2617-29252021-11-014210.31636/prmd.v4i2.1The effectiveness of moxifloxacin in the treatment of community-acquired pneumoniaDmytro Dmytriiev0Oleksandr Nazarchuk1Yuliana Babina2National Pirogov Memorial Medical University, VinnytsiaNational Pirogov Memorial Medical University, VinnytsiaNational Pirogov Memorial Medical University, VinnytsiaThe article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent.https://perioperative.org.ua/index.php/prtmdc/article/view/78fluoroquinolonesmoxifloxacintreatmentpneumoniaCOVID-19 |
| spellingShingle | Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia Perioperative Medicine fluoroquinolones moxifloxacin treatment pneumonia COVID-19 |
| title | The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_full | The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_fullStr | The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_full_unstemmed | The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_short | The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_sort | effectiveness of moxifloxacin in the treatment of community acquired pneumonia |
| topic | fluoroquinolones moxifloxacin treatment pneumonia COVID-19 |
| url | https://perioperative.org.ua/index.php/prtmdc/article/view/78 |
| work_keys_str_mv | AT dmytrodmytriiev theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT oleksandrnazarchuk theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT yulianababina theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT dmytrodmytriiev effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT oleksandrnazarchuk effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT yulianababina effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia |